Jennifer Chester, MD
Allergy & Immunology · New York, NYNPI 1588930069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,321 of the $2,121 with a category attached, or 62.3%. Sanofi accounts for 67.9% of it on its own, with 9 other manufacturers making up the rest. That places this record below the midpoint for allergy & immunology clinicians in NY, where the typical reported total is $2,174.
Across 23 payments — averaging $92.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- Organon$164
- Biocryst US Sales Co., LLC$148
- Novartis$125
- AstraZeneca$73
- E.r. Squibb & Sons, L.L.C.$59
- plus $111 from 4 others
What the payments were for
- Grants$80038%
- Food & beverage$1,32162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 8 | $1,440 |
| Organon | 1 | $164 |
| Biocryst US Sales Co., LLC | 1 | $148 |
| Novartis | 1 | $125 |
| AstraZeneca | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Johnson & Johnson | 3 | $45 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| AbbVie | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,121 in reported general payments places this provider in the 45th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $46,074 |
| Fluticasone Propionate | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in New York
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$946K
- Richard InselNew York$269K
- Purvi ParikhNew York$183K
- Arthur LubitzNew York$165K
- Ama AlexisNew York$120K
- Boyan HadjievNew York$97K
- Charlotte Cunningham-RundlesNew York$95K
- Paula BusseNew York$95K
- Hale YarmohammadiNew York$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.